How safe are GLP-1 weight loss medications?

Whether a GLP-1 weight-loss medicine is safe for you depends on the specific medication, the formulation, and your own health history. This article covers semaglutide (Wegovy) and tirzepatide (Zepbound), drawing on current prescribing information, clinical trials, FDA guidance, and published research. It is not individualized medical advice; discuss with your clinician which risks apply to you.

• Nausea, diarrhea, vomiting, and constipation are among the most common side effects of both Wegovy and Zepbound, and nausea, vomiting, and diarrhea are reported mostly while the dose is being increased.
• Both labels warn about pancreatitis, gallbladder disease, dehydration-related kidney injury, and serious allergic reactions, and both carry a boxed warning about thyroid tumors in rodents.
• Signs of a serious allergic reaction, or severe stomach pain that will not go away, need prompt medical attention.
• In the SELECT trial, semaglutide reduced major adverse cardiovascular events by 20% in adults with cardiovascular disease and overweight or obesity but without diabetes.
• Compounded versions are not FDA approved, and the FDA has warned about dosing errors, fraudulent labels, and shipments that arrived warm.
• People switched to placebo in withdrawal studies of either medicine regained weight.

The most frequently reported side effects of GLP-1 medications are gastrointestinal. Both the Wegovy and Zepbound labels list nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, fatigue, and hair loss among the most common; headache and dizziness are also common with Wegovy, and injection site reactions with Zepbound.

In Wegovy's adult weight-reduction trials, 73% of people taking the injection reported gastrointestinal side effects, compared with 47% taking placebo; nausea affected 44% versus 16%. In two pooled Zepbound trials, 56% reported them at each dose, compared with 30% taking placebo, and nausea affected 25% to 29% versus 8%. For both medicines these symptoms were reported mostly during dose escalation, which is one reason treatment starts at a low dose and increases gradually.

Side effects led 6.8% of people taking Wegovy 2.4 mg to stop treatment, compared with 3.2% taking placebo, and 4.8% to 6.7% of people taking Zepbound, compared with 3.4%, most often because of gastrointestinal symptoms. Severe gastrointestinal reactions affected 4.1% of people on the Wegovy injection versus 0.9% on placebo, and 1.7% to 3.1% on Zepbound versus 1%.

Vomiting or diarrhea that causes dehydration can lead to kidney injury. If side effects make it hard to drink, eat, or take other medicines, contact the prescriber; dose escalation may need to pause.

Pancreatitis and gallbladder disease

Both labels warn that acute pancreatitis, including fatal cases, has occurred with GLP-1 receptor agonists; warning signs include persistent or severe abdominal pain, sometimes spreading to the back. Recent weight-loss trials of semaglutide and tirzepatide have not shown increased rates of pancreatitis. Gallstones were reported by 1.6% of adults taking the Wegovy injection versus 0.7% on placebo, and by 1.1% taking Zepbound versus 1%.

Muscle and bone health

Weight loss includes lean tissue as well as fat. In the STEP 1 trial of semaglutide, 38% of the average 13.6 kg weight reduction was lean body mass, and in SURMOUNT-1, tirzepatide reduced total lean mass by 8.5 absolute percentage points. More protein alone is likely inadequate to preserve muscle without structured strength training, and in one randomized trial, one year of GLP-1 therapy alone decreased bone mineral density, while adding exercise training preserved it. Older adults and people with osteoporosis should raise muscle and bone health with their clinician.

Vision

Both labels advise monitoring people with type 2 diabetes who have a history of diabetic retinopathy. GLP-1 medicines have also been associated with nonarteritic anterior ischemic optic neuropathy (NAION), an optic nerve condition; most cases occurred in people with type 2 diabetes, and whether the risk is the same without diabetes is unclear.

Thyroid tumors in animal studies

Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents. The human relevance is unknown, and the medicines are contraindicated for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Human studies of thyroid cancer risk have produced mixed results.

For Wegovy, stop the medicine and get medical help right away for signs of a serious allergic reaction, such as problems breathing or swallowing or swelling of the face, lips, tongue, or throat. Stop it and call the prescriber right away for severe stomach pain that will not go away. The Zepbound label similarly advises stopping the medicine and promptly seeking medical attention if a serious allergic reaction is suspected.

Any honest safety assessment includes benefits alongside risks. Ozempic is approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and Wegovy in adults with established cardiovascular disease and obesity or overweight. Zepbound's label does not include a cardiovascular indication.

SELECT enrolled 17,604 adults with preexisting cardiovascular disease and overweight or obesity, without diabetes. Weight loss with semaglutide was sustained for up to four years; at 208 weeks, weight was down 10.2% versus 1.5% with placebo. Serious adverse events were reported by 33.4% of participants taking semaglutide and 36.4% taking placebo, but side effects led 16.6% to stop the drug, versus 8.2%. These results apply to semaglutide in the SELECT population, not to every GLP-1 medicine or to lifetime use.

Compounded drugs are not FDA approved, and the FDA does not review them for safety, effectiveness, or quality before they are marketed. The agency has received reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide, as well as reports tied to doses beyond the approved labels. As of May 31, 2026, it had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, likely an undercount because federal law does not require every compounding pharmacy to report them.

Other concerns include salt forms of semaglutide that are different active ingredients from those in approved drugs, fraudulent labels naming pharmacies that did not make the product, and injectable products that arrived warm. Retatrutide and cagrilintide cannot legally be used in compounding.

The FDA recommends getting a prescription from your doctor and filling it at a state-licensed pharmacy. Warning signs include claims that a compounded drug is the same as an approved one, prices that seem too good to be true, and no required screening. Ask for the exact product name, concentration, dose units, and measuring device before using any product.

Weight regain after stopping is well documented. In randomized withdrawal studies, people switched from semaglutide or tirzepatide to placebo regained weight even though they had been prescribed a reduced-calorie diet and more physical activity. In one extension study, semaglutide was stopped at 68 weeks; by 120 weeks, people had regained weight but kept a net loss of 5.6%. This is not a safety risk in the traditional sense, but it matters for planning: discuss how long treatment is expected to last before you start.

The lack of long-term clinical trials in weight management means clinicians must consider potentially unforeseen long-term side effects. Whether weight loss with these medicines changes the balance of fat and lean mass is also unresolved, and more study is needed for people with sarcopenic obesity.

Several topics are worth covering before starting treatment and throughout it.

• Your risk factors, including prior pancreatitis or gallbladder disease, kidney problems, diabetic retinopathy, bone or muscle concerns, and pregnancy plans.
• Every prescription and over-the-counter medicine you take.
• Which symptoms are expected and which need a call or urgent care.
• Whether your product is FDA approved and dispensed by a licensed pharmacy.
• What follow-up will look like, and what stopping would mean for you.
• Any planned surgery or deep sedation, because both labels warn about pulmonary aspiration during anesthesia.

Are GLP-1 weight loss drugs safe for long-term use?

SELECT followed semaglutide users for up to four years, with fewer serious adverse events than placebo, but long-term weight-management trials are still lacking.

What are the most common side effects of semaglutide and tirzepatide?

Nausea, vomiting, diarrhea, and constipation are among the most common; nausea, vomiting, and diarrhea are reported mostly during dose increases.

Can GLP-1 drugs cause serious harm?

They can: both labels warn about pancreatitis, gallbladder disease, kidney injury from dehydration, severe gastrointestinal reactions, and serious allergic reactions. Compounded versions add risks from dosing errors and fraudulent products.

Is it safe to use compounded semaglutide or tirzepatide?

The FDA does not review compounded versions for safety, effectiveness, or quality, and it recommends them only when an FDA-approved drug cannot meet a patient's medical needs.

Do GLP-1 medications cause muscle loss?

Some of the weight lost is lean mass: 38% in the STEP 1 semaglutide trial. Resistance exercise and adequate protein help limit it.

Can these drugs affect my bones or increase fracture risk?

They may. In one randomized trial, GLP-1 therapy alone reduced bone mineral density over a year, while adding exercise preserved it. If you have osteoporosis or related risk factors, raise this with your doctor before starting treatment.

Is there a link between GLP-1 drugs and vision problems?

GLP-1 use has been associated with NAION, an optic nerve condition, mostly in people with type 2 diabetes. This is worth discussing with your doctor if you have existing eye conditions or optic nerve risk factors.

Will I gain the weight back if I stop taking a GLP-1 medication?

Weight regain after stopping is common and well-documented. Understanding it before you start helps you and your clinician build a realistic long-term plan.

How do I know if my GLP-1 prescription is legitimate?

Get it from your doctor and fill it at a state-licensed pharmacy, as the FDA recommends. Injectable GLP-1 medicines require refrigeration, and the FDA advises not using one that arrives warm.

Are GLP-1 drugs safe for older adults?

Older age is linked to greater muscle loss during weight reduction, so muscle and bone health deserve closer attention. An individualized discussion with a clinician who knows your health history is especially important.